Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- ZAIPUT FLOW TECHNOLOGIES LLC
- Proposal award date
- 2025-06-05
- Contract end date
- 2027-05-31
- UEI
- J4H2SN6EYA94
- Solicitation number
- NSF 24-580
- Topic code
- CT
Research abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is to improve a key step used in the >$500-billion market of pharmaceutical manufacturing: purification of active pharmaceutical ingredients (APIs). 90% of all APIs are purified using crystallization, however, the current, mainly batch-based, approaches available have drawbacks from both the commercial and scientific points of view. Current techniques are difficult to scale up, are expensive to maintain and manufacture, and are plagued by inconsistency and lack of uniformity in conditions and results. With the development and commercialization of the Scalable Continuous Crystallizer technology proposed here, the company will address the scalability, cost, and inconsistency issues in order to: 1) speed up the transition to advanced manufacturing approaches (Continuous Manufacturing), 2) facilitate the re-shoring of drug manufacturing, contributing to addressing the national security challenge of American dependence on foreign drug manufacturers, and 3) reduce drug production costs, which will eventually lead to cheaper drugs for the benefit of the entire population. In summary, the commercialization of this technology may increase the adoption of advanced technologies, reduce national security risks, and cut the overall costs of pharmaceutical manufacturing.
This SBIR Phase II project proposes to further the development of an innovative continuous crystallization device that is expected to be scalable, provide adequate and effective movement of solids, and provide high-quality crystal products, thus fulfilling an unmet need in the pharmaceutical market and in the technical community. The novel design aims to solve the problem of moving solids (crystals) effectively while providing well-controlled flow characteristics with an approach that is scalable from lab to production. The company’s patent-pending Scalable Continuous Crystallizer technology uses a combination
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Research funding history
4 SBIR/STTR records share this UEI (2021–2025). Reported award amounts total $3,272,335. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services, National Science Foundation
Agency intelligence
National Science Foundation
Back to SBIR/STTR Research Awards